ConductScience.org, home

Paper33705209

Next-Generation Endocrine Therapies for Breast Cancer.

McDonnell DP and 3 others. J Clin Oncol, 2021. Cited by 35 papers, by iCite.

Cite this record

ConductScience Library. Next-Generation Endocrine Therapies for Breast Cancer. Papers, record 33705209. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/33705209

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Next-Generation Endocrine Therapies for Breast Cancer.
PubMed
Journal
J Clin Oncol
PubMed
Year
2021
PubMed
Publication types
Journal Article, Research Support, U.S. Gov't, Non-P.H.S.
PubMed
Citations, by iCite
35
iCite
Relative citation ratio, by iCite
1.7
iCite
Revised in PubMed
2022-04-21
PubMed

Authors4

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1McDonnell DPDonald Phttps://orcid.org/0000-0002-7331-4700
2Wardell SESuzanne Ehttps://orcid.org/0000-0002-5792-1447
3Chang CYChing-Yi
4Norris JDJohn D

Source PubMed

Download CSV of authors

Topics7

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antineoplastic Agents, HormonalMajor topic
Breast NeoplasmsMajor topic
Estrogen Receptor alpha
Female
Humans
Mutation
Selective Estrogen Receptor Modulators

Source PubMed

Download CSV of topics

References55

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
119875750Activity of fulvestrant in HER2-overexpressing advanced breast cancer.Ann Oncol2010https://conductscience.org/library/papers/19875750PubMed
210426998Peptide antagonists of the human estrogen receptor.Science1999https://conductscience.org/library/papers/10426998PubMed
38275477Investigation of a new pure antiestrogen (ICI 182780) in women with primary breast cancer.Cancer Res1994https://conductscience.org/library/papers/8275477PubMed
410424402Randomized trial of diethylstilbestrol vs. tamoxifen in postmenopausal women with metastatic breast cancer. An updated analysis.Breast Cancer Res Treat1999https://conductscience.org/library/papers/10424402PubMed
510579349Comparative analyses of mechanistic differences among antiestrogens.Endocrinology1999https://conductscience.org/library/papers/10579349PubMed
624803577The microenvironment matters: estrogen deficiency fuels cancer bone metastases.Clin Cancer Res2014https://conductscience.org/library/papers/24803577PubMed
733513026Phase I Study of Elacestrant (RAD1901), a Novel Selective Estrogen Receptor Degrader, in ER-Positive, HER2-Negative Advanced Breast Cancer.J Clin Oncol2021https://conductscience.org/library/papers/33513026PubMed
815814849Transcriptional regulation by steroid receptor coactivator phosphorylation.Endocr Rev2005https://conductscience.org/library/papers/15814849PubMed
931091374Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer.N Engl J Med2019https://conductscience.org/library/papers/31091374PubMed
108592512Analysis of estrogen receptor function in vitro reveals three distinct classes of antiestrogens.Mol Endocrinol1995https://conductscience.org/library/papers/8592512PubMed
1129991605Discovery of Selective Estrogen Receptor Covalent Antagonists for the Treatment of ERαWT and ERαMUT Breast Cancer.Cancer Discov2018https://conductscience.org/library/papers/29991605PubMed
121749936Dopaminergic and ligand-independent activation of steroid hormone receptors.Science1991https://conductscience.org/library/papers/1749936PubMed
1326162914Evaluation of the pharmacological activities of RAD1901, a selective estrogen receptor degrader.Endocr Relat Cancer2015https://conductscience.org/library/papers/26162914PubMed
1421051656Breast cancer incidence in the randomized PEARL trial of lasofoxifene in postmenopausal osteoporotic women.J Natl Cancer Inst2010https://conductscience.org/library/papers/21051656PubMed
1511306468Circumventing tamoxifen resistance in breast cancers using antiestrogens that induce unique conformational changes in the estrogen receptor.Cancer Res2001https://conductscience.org/library/papers/11306468PubMed
165767298Estrogen receptors in the rat uterus. Studies on the interaction of cytosol and nuclear binding sites.J Biol Chem1969https://conductscience.org/library/papers/5767298PubMed
179881323Post-menopausal women and osteoporosis: available choices for maintenance of skeletal health.Maturitas1998https://conductscience.org/library/papers/9881323PubMed
186066766A new derivative of triphenylethylene: effect on implantation and mode of action in rats.J Reprod Fertil1967https://conductscience.org/library/papers/6066766PubMed
197001242Randomized clinical trial of diethylstilbestrol versus tamoxifen in postmenopausal women with advanced breast cancer.N Engl J Med1981https://conductscience.org/library/papers/7001242PubMed
206438654The pharmacology and clinical uses of tamoxifen.Pharmacol Ther1984https://conductscience.org/library/papers/6438654PubMed

See all 55 referencesDownload CSV of references

Cited by28

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 35 citations.

PMIDTitleJournalYearIn PapersSource
42948694Post CDK4/6 inhibitors: Novel targeted combinations based on SERDs in HR+/HER2- advanced breast cancer.Acta Pharm Sin B2026https://conductscience.org/library/papers/42948694PubMed
42072376Research Progress of PROTACs in Breast Cancer: Subtype-Oriented Target Landscape, Clinical Stratification Evidence, and Engineering Strategies for Translation.Biomedicines2026https://conductscience.org/library/papers/42072376PubMed
41999452Beyond CDK4/6 Inhibition: Current Strategies in Hormone Receptor-Positive Metastatic Breast Cancer.Curr Treat Options Oncol2026https://conductscience.org/library/papers/41999452PubMed
41301715Estrogen Receptors as Key Factors in Carcinogenesis.Biomedicines2025https://conductscience.org/library/papers/41301715PubMed
41285747A ternary switch model governing ERα ligand binding domain conformation.Nat Commun2025https://conductscience.org/library/papers/41285747PubMed
41171336Research progress of DUB enzyme in breast cancer.Clin Exp Med2025https://conductscience.org/library/papers/41171336PubMed
40696170PROTAC SERD vepdegestrant outperforms fulvestrant for advanced-stage ER+HER2- breast cancer harbouring acquired ESR1 mutations.Nat Rev Clin Oncol2025https://conductscience.org/library/papers/40696170PubMed
40303343Sex bias in tumor immunity: insights from immune cells.Theranostics2025https://conductscience.org/library/papers/40303343PubMed
40103456Analysis of the Main Directions in the Development of Mono and Combination Pharmacotherapy Acting on Hormonal Signaling Pathways of Breast Cancer According to the FDA Databases and Clinicaltrials.gov.Curr Med Chem2025https://conductscience.org/library/papers/40103456PubMed
39966355Breast cancer: pathogenesis and treatments.Signal Transduct Target Ther2025https://conductscience.org/library/papers/39966355PubMed
39891710Interaction between Estrogen Receptors and p53: A Broader Role for Tamoxifen?Endocrinology2025https://conductscience.org/library/papers/39891710PubMed
39820652Elacestrant in Women with Estrogen Receptor-Positive and HER2-Negative Early Breast Cancer: Results from the Preoperative Window-of-Opportunity ELIPSE Trial.Clin Cancer Res2025https://conductscience.org/library/papers/39820652PubMed
39702552The EstroGene2.0 database for endocrine therapy response and resistance in breast cancer.NPJ Breast Cancer2024https://conductscience.org/library/papers/39702552PubMed
39519751Antioxidant 1,2,3,4,6-Penta-O-galloyl-β-D-glucose Alleviating Apoptosis and Promoting Bone Formation Is Associated with Estrogen Receptors.Molecules2024https://conductscience.org/library/papers/39519751PubMed
39331714Estrogen signaling suppresses tumor-associated tissue eosinophilia to promote breast tumor growth.Sci Adv2024https://conductscience.org/library/papers/39331714PubMed
38435754Anti-Cancer Potency of Copper-Doped Carbon Quantum Dots Against Breast Cancer Progression.Int J Nanomedicine2024https://conductscience.org/library/papers/38435754PubMed
38028803Targeting estrogen signaling and biosynthesis for aged skin repair.Front Physiol2023https://conductscience.org/library/papers/38028803PubMed
37684402Targeting sex steroid biosynthesis for breast and prostate cancer therapy.Nat Rev Cancer2023https://conductscience.org/library/papers/37684402PubMed
37684290Emerging systemic therapy options beyond CDK4/6 inhibitors for hormone receptor-positive HER2-negative advanced breast cancer.NPJ Breast Cancer2023https://conductscience.org/library/papers/37684290PubMed
37193881The G protein-coupled oestrogen receptor GPER in health and disease: an update.Nat Rev Endocrinol2023https://conductscience.org/library/papers/37193881PubMed

See all 28 cited byDownload CSV of cited by

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
ESR12099PubTator's text mininghttps://conductscience.org/library/genes/2099

Source NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/33705209

GET https://conductscience.org/api/papers/v1/33705209/references?page=2